Epilepsy Treatment in Patients with Heart Disease

AbstractPurpose of reviewThis review highlights issues pertaining to the treatment of seizures in patients with cardiac disease. These fall into two categories: impacts upon the native disease — primarily an issue with coronary artery disease and arrhythmia — and drug interactions, which are important in all types of cardiac disease.Recent findingsA sizeable body of evidence indicates that enzyme-inducing anti-seizure medications (EIASMs) increase serum lipids and other serological and surrogate markers of vascular risk. A recent large epidemiologic study confirmed that patients treated with EIASMs are at significantly increased risk for cardiovascular disease. A recent Food and Drug Administration (FDA) alert highlighted the potential risk of arrhythmia in lamotrigine-treated patients with underlying cardiac disease; however, subsequent investigations have yielded, at best, only modest support for this concern.SummaryEIASMs are poor choices for patients with cardiac disease due to their propensity to cause drug interactions, and the multiple lines of evidence suggest that they exacerbate coronary artery disease. The FDA and epilepsy societies have recently highlighted the potential for exacerbation of arrhythmia with the use of lamotrigine; however, data to support this appears marginal, and more work is needed.
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research